BiotechTube

Ustekinumab 45 mg + Ustekinumab 90 mg

Pre-clinicalRecruiting
0 watching 0 views this week💤 Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Crohn Disease

Conditions

Crohn Disease, Plaque Psoriasis

Trial Timeline

Mar 17, 2025 → Dec 31, 2027

NCT ID
NCT06997055

About Ustekinumab 45 mg + Ustekinumab 90 mg

Ustekinumab 45 mg + Ustekinumab 90 mg is a pre-clinical stage product being developed by Celltrion for Crohn Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06997055. Target conditions include Crohn Disease, Plaque Psoriasis.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT06997055Pre-clinicalRecruiting

Competing Products

20 competing products in Crohn Disease

See all competitors
ProductCompanyStageHype Score
VTX958 + VTX958 + VTX958 PlaceboVentyx BiosciencesPhase 2
47
LY4395089 + Mirikizumab - Intravenous (IV) + Mirikizumab - Subcutaneous (SC)Eli LillyPhase 2
52
CT-P13 + RemicadeCelltrionPhase 3
77
Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate)CelltrionApproved
85
CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13CelltrionPhase 1
33
CT-P13 SC (Infliximab)CelltrionPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
CP-461Astellas PharmaPhase 2
52
UstekinumabSun PharmaceuticalPre-clinical
23
E6011 2 mg/kg + E6011 5 mg/kg + E6011 10 mg/kg + E6011 15 mg/kgEisaiPhase 1/2
41
E6011 + PlaceboEisaiPhase 2
52
E6011 + PlaceboEisaiPhase 1
33
adalimumab + adalimumab + placeboEisaiPhase 2/3
65
adalimumabEisaiPhase 2/3
65
Mirikizumab + Mirikizumab + Ustekinumab + Ustekinumab + Placebo + PlaceboEli LillyPhase 3
77
MirikizumabEli LillyPhase 3
77
Mirikizumab + Mirikizumab + Tirzepatide + PlaceboEli LillyPhase 3
77
Mirikizumab + PlaceboEli LillyPhase 2
52
MirikizumabEli LillyPhase 3
77

Other Products from Celltrion

Azathioprine + PlaceboApproved
85
Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate)Approved
85
Infliximab + Infliximab + InfliximabApproved
85
Pioglitazone + Alogliptin + Alogliptin + Metformin + DapagliflozinApproved
85
Pioglitazone 15 MG [Actos] + Empagliflozin 10 MG [Jardiance] + Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]Approved
85